The Holistic Pharmacy Approach To 340B Patient Support

September 8, 2025340B, Bedside Prescription Delivery, Contract Pharmacy, Drug Manufacturer Restrictions, Meds To Beds, Patient Eligibility, PBM, Readmissions Reduction, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy, Uncategorized, Value-Based Care

How to make Pharmacy “The Easy Part” of the patient experience. Anyone who’s ever been a hospital patient, or patient caregiver, knows that the mental strain of a serious illness can often match the negative impact of the physical trauma. Particularly when an illness is chronic and/or long-term, the stress involved in managing the details … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

February 15, 2024340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when VytlOne launched its 340B Support Services division, we’ve managed the 340B programs of 21 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

October 19, 2023340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when VytlOne launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. We’ve generated more than $500 million in 340B Savings and Revenue. And yet, we’ve never served (or seen) a 340B health system with … Read More

340B ESP Terms Of Use Set Tone For Demands On Covered Entities

August 18, 2022Uncategorized

What does it mean for covered entities already desperate for diminishing 340B savings and revenue? As we noted in a previous post, 340B ESP is nothing less than a brazen and (in our opinion) unlawful ploy by the drug manufacturers to evade the discounts they are legally obligated to offer eligible entities — by placing … Read More